

Form 101 (Rev. 11-97)

U.S. Dept. of Commerce
Patent and Trademark Office

ATTY. DOCKET NO.

SERIAL NO.

HUBR 1198 (1011154)

Please assign

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

APPLICANT

Kratz

FILING DATE

herewith

GROUP

To Be Assigned

U.S. PATENT DOCUMENTS

*Examiner Initial	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (if appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
RT	196 36 889	3 12 98	DE				
I	00 76550	12 21 00	WO				

OTHER DOCUMENTS

(INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

RT	4	Kratz, et al "Preparation, Characterization and In Vitro.....Doxorubicin", Biological & Pharm. Bulletin, Pharm. Soc. of Japan, Vol. 21, No. 1, 1998, pages 56-61
	1	A. Trouet, et al, "A covalent linkage between daunorubicin and proteins that isin vivo studies", Proceedings of the National Academy of Sciences of USA, Vol. 79, 1:82 (pages 626-629.
	1	S. Netzel-Arnett, "Comparative Sequence..... (Matrilysin", Biochemistry, Vol. 32, No. 25, 1993, pages 6427-6432.
	1	M. Nichifor et al: "Macromolecular prodrugs of 5-fluorouracil ...degradation", Journal of Controlled release, Vol. 39, 1996, pages 79-92.
	1	G. M. Dubowchik et al: "Cathepsin B-sensitive dipeptide prodrugs. 1. A model study.....doxorubicin", Biorg. Med. Chem. Lett. Vol. 8, No. 23, pages 3341-3346.
	1	M. Kruger, et al: "synthesis and stability of four maleimide.....chemoimmunoanjugates", Biological & Pharm. Bull. of Japan, Vol. 45, No. 2, 1997, pages 399-401.

EXAMINER

R. Teller

DATE CONSIDERED

12/22/03

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.